



# UK Health Security Agency




This document provides a notice of extension of the validity of the following PGD:

## UKHSA Publications gateway number: GOV-15000

Reference no: Zostavax® PGD  
Version no: v11.00  
Valid from: 1 September 2023  
Expiry date: 30 June 2024 (Extended to **31 October 2024**)


This PGD is extended and valid until 31 October 2024, reflecting the longest-dated shelf life of centrally supplied stock of Zostavax®, following its phasing out from the shingles vaccination programme.


This extension is approved by the following health professionals on behalf of UKHSA:

Developed by:	Name	Signature	Date
<b>Pharmacist</b> (Lead Author)	Christina Wilson Lead Pharmacist – Immunisation Services, Immunisation and Vaccine Preventable Diseases Division, UKHSA		2 November 2023
<b>Doctor</b>	Dr Gayatri Amirthalingam Deputy Director of Public Health Programmes and Consultant Medical Epidemiologist, Immunisation and Vaccine Preventable Diseases Division, UKHSA		2 November 2023
<b>Registered Nurse</b> (Chair of Expert Panel)	David Green Nurse Consultant – Immunisation and Vaccine Preventable Diseases Division, UKHSA		2 November 2023

This extension has been approved by the UKHSA Medicines Governance Committee.

NHS Greater Manchester Integrated Care authorises this extension and continued use of Zostavax® PGD v11.00 during the assigned period by the services or providers listed below:

<b>Authorised for use by the following organisations and/or services</b>			
<b>All NHS England commissioned immunisation services.</b>			
<b>Limitations to authorisation</b>			
<b>Organisational approval (legal requirement)</b>			
<b>Role</b>	<b>Name</b>	<b>Sign</b>	<b>Date</b>
Chief Medical Officer	Professor Manisha Kumar		18/12/2023

<b>Additional signatories according to locally agreed policy</b>			
<b>Role</b>	<b>Name</b>	<b>Sign</b>	<b>Date</b>
Deputy Chief Nursing Officer	Anita Rolfe		18/12/2023